NCT06925984View on ClinicalTrials.gov

Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast)

NANot yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

May 1, 2028

Study Completion Date

May 1, 2030

Conditions
OligoProgressive Metastatic Disease
Interventions
RADIATION

SBRT

SBRT of all oligoprogressive metastases (or other local therapy if SBRT not advisable), followed by continuation of the same systemic therapy.

Trial Locations (5)

Unknown

Jules Bordet Institute, Brussels

UZ Gent, Ghent

AZ Groeninge, Kortrijk

AZ Sint-Maarten, Mechelen

CHU UCL Namur - Site Saint Elisabeth, Namur

Sponsors
All Listed Sponsors
lead

Jules Bordet Institute

OTHER

NCT06925984 - Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast) | Biotech Hunter | Biotech Hunter